"Anticholesteremic Agents" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Substances used to lower plasma CHOLESTEROL levels.
| Descriptor ID |
D000924
|
| MeSH Number(s) |
D27.505.519.186.071.202 D27.505.954.557.500.202
|
| Concept/Terms |
Anticholesteremic Agents- Anticholesteremic Agents
- Agents, Anticholesteremic
- Inhibitors, Cholesterol
- Cholesterol Inhibitors
- Anticholesteremic Drugs
- Drugs, Anticholesteremic
- Anticholesteremics
|
Below are MeSH descriptors whose meaning is more general than "Anticholesteremic Agents".
Below are MeSH descriptors whose meaning is more specific than "Anticholesteremic Agents".
This graph shows the total number of publications written about "Anticholesteremic Agents" by people in this website by year, and whether "Anticholesteremic Agents" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1997 | 1 | 0 | 1 |
| 1998 | 1 | 0 | 1 |
| 2003 | 1 | 0 | 1 |
| 2004 | 1 | 0 | 1 |
| 2005 | 0 | 1 | 1 |
| 2008 | 3 | 0 | 3 |
| 2009 | 3 | 0 | 3 |
| 2010 | 2 | 0 | 2 |
| 2011 | 1 | 0 | 1 |
| 2012 | 1 | 1 | 2 |
| 2014 | 2 | 0 | 2 |
| 2016 | 2 | 3 | 5 |
| 2017 | 4 | 0 | 4 |
| 2018 | 2 | 2 | 4 |
| 2019 | 3 | 0 | 3 |
| 2020 | 4 | 0 | 4 |
| 2022 | 3 | 0 | 3 |
To return to the timeline,
click here.
Below are the most recent publications written about "Anticholesteremic Agents" by people in Profiles.
-
2022 ACC Expert Consensus Decision Pathway on the Role of Nonstatin Therapies for LDL-Cholesterol Lowering in the Management of Atherosclerotic Cardiovascular Disease Risk: A Report of the American College of Cardiology Solution Set Oversight Committee. J Am Coll Cardiol. 2022 10 04; 80(14):1366-1418.
-
Reducing Disparities in Cholesterol Control. JAMA. 2022 08 23; 328(8):714-716.
-
Apolipoprotein B, Residual Cardiovascular Risk After Acute Coronary Syndrome, and Effects of Alirocumab. Circulation. 2022 Aug 30; 146(9):657-672.
-
Lipoprotein(a) lowering by alirocumab reduces the total burden of cardiovascular events independent of low-density lipoprotein cholesterol lowering: ODYSSEY OUTCOMES trial. Eur Heart J. 2020 11 21; 41(44):4245-4255.
-
Cholesterol reducer and thrombolytic therapy in acute ischemic stroke patients. Lipids Health Dis. 2020 May 06; 19(1):84.
-
Lovastatin protects against cisplatin-induced hearing loss in mice. Hear Res. 2020 04; 389:107905.
-
Sustained Low-Density Lipoprotein Cholesterol Lowering With Alirocumab in ODYSSEY?OUTCOMES. J Am Coll Cardiol. 2020 02 04; 75(4):448-451.
-
Risk Categorization Using New American College of Cardiology/American Heart Association Guidelines for Cholesterol Management and Its Relation to Alirocumab Treatment Following Acute Coronary Syndromes. Circulation. 2019 11 05; 140(19):1578-1589.
-
Very High-Risk ASCVD and Eligibility for Nonstatin Therapies Based on the 2018?AHA/ACC Cholesterol Guidelines. J Am Coll Cardiol. 2019 08 06; 74(5):712-714.
-
Applicability and Cost Implications for Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors Based on the ODYSSEY Outcomes Trial. Circulation. 2019 01 15; 139(3):410-412.